Uploads Contact
/
Login Upload

  • Search Results for 'Phase I Study Of Olaparib And Temozolomide In Patients With Recurrent And Or Metastatic Ewing'

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic
alexa-scheidler
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic
karlyn-bohler
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor,
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor,
marina-yarberry
Management of metastatic and recurrent head and neck cancer
Management of metastatic and recurrent head and neck cancer
liane-varnes
Case Discussion: Second
Case Discussion: Second
celsa-spraggs
NEw developments IN gynecological Oncology
NEw developments IN gynecological Oncology
cheryl-pisano
Challenging Case Study: VTE Treatment- “How Long is Long Enough?”
Challenging Case Study: VTE Treatment- “How Long is Long Enough?”
olivia-moreira
SARC020 – EORTC 62091 TRUSTS – A phase IIb/III multicenter study comparing the efficacy
SARC020 – EORTC 62091 TRUSTS – A phase IIb/III multicenter study comparing the efficacy
tatiana-dople
Recurrent Miscarriage:
Recurrent Miscarriage:
ellena-manuel
ADVANCES IN THERAPY FOR SARCOMA AND GIST
ADVANCES IN THERAPY FOR SARCOMA AND GIST
ellena-manuel
Patient Selection for PARP
Patient Selection for PARP
sherrill-nordquist
Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
myesha-ticknor
PARP Inhibitors and Cancer: What Do You Need to Know?
PARP Inhibitors and Cancer: What Do You Need to Know?
pasty-toler
phase ii STUDY designs:
phase ii STUDY designs:
calandra-battersby
The EINSTEIN EXT Study 'Xarelto' for
The EINSTEIN EXT Study 'Xarelto' for
tatiana-dople
update in metastatic breast c
update in metastatic breast c
min-jolicoeur
PARP Inhibitors This program will include a discussion of off-label treatment and investigational
PARP Inhibitors This program will include a discussion of off-label treatment and investigational
conchita-marotz
New Perspectives for Your nAMD Patients
New Perspectives for Your nAMD Patients
pamella-moone
THE NUMBER OF RESECTED NON METASTATIC LYMPH NODES PREDICTS
THE NUMBER OF RESECTED NON METASTATIC LYMPH NODES PREDICTS
conchita-marotz
Phase II designs in Oncology
Phase II designs in Oncology
stefany-barnette
update in metastatic breast cancer
update in metastatic breast cancer
calandra-battersby
Recurrent HL after Auto
Recurrent HL after Auto
karlyn-bohler
DEVELOPMENT OF
DEVELOPMENT OF
olivia-moreira
Improving Adverse Drug Reaction Information in Product Labels
Improving Adverse Drug Reaction Information in Product Labels
liane-varnes